Novartis And Beijing Hospital Sign Agreement On Clinical Trial Collaboration
This article was originally published in PharmAsia News
China Novartis Institutes for Biomedical Research and Beijing Hospital have signed an agreement framework on clinical trial collaboration. Under the agreement, Novartis will help the hospital set up international standardized trial protocols and fund clinical researchers for domestic and overseas training. In addition, the firm promises to accord priority to Beijing Hospital in conducting its trial projects, while the hospital will give preference to Novartis' projects. The complementary collaboration will allow both partners to improve the efficiency of new drug clinical research as well as guarantee drug safety and effectiveness. (Click here for more - Chinese Language)
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.